Rhesus Blood Group, CcEe Antigens (RHCE) (Middle Region) Peptid
RHCE
Reaktivität: Human
Wirt: Synthetic
WB, BP
Produktnummer ABIN5512453
Kurzübersicht für Rhesus Blood Group, CcEe Antigens (RHCE) (Middle Region) Peptid (ABIN5512453)
Target
RHCE
(Rhesus Blood Group, CcEe Antigens (RHCE))
Spezies
Human
Quelle
Synthetic
Applikation
Western Blotting (WB), Blocking Peptide (BP)
-
-
Protein Region
- Middle Region
-
Sequenz
- VAWCLPKPLP KGTEDNDQRA TIPSLSAMLG ALFLWMFWPS VNSPLLRSPI
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-RHCE Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- RHCE (Rhesus Blood Group, CcEe Antigens (RHCE))
-
Hintergrund
-
The Rh blood group system is the second most clinically significant of the blood groups, second only to ABO. It is also the most polymorphic of the blood groups, with variations due to deletions, gene conversions, and missense mutations. The Rh blood group includes this gene which encodes both the RhC and RhE antigens on a single polypeptide and a second gene which encodes the RhD protein. The classification of Rh-positive and Rh-negative individuals is determined by the presence or absence of the highly immunogenic RhD protein on the surface of erythrocytes. A mutation in this gene results in amorph-type Rh-null disease.
Protein Size: 244 -
Gen-ID
- 6006
Target
-
Sie sind hier:
